Chlorophenothane


ToxCast endpoints for intended target type: RNA
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
LTEA_HepaRG_ABCC2LiverHuman1244ABCC2Inhibitory4.19 μM
LTEA_HepaRG_ABCG2LiverHuman9429ABCG2Inhibitory0.79 μM
LTEA_HepaRG_CYP1A1LiverHuman1543CYP1A1Inhibitory9.54 μM
LTEA_HepaRG_CYP2B6LiverHuman1555CYP2B6Inhibitory1.14 μM
LTEA_HepaRG_CYP2C19LiverHuman1557CYP2C19Inhibitory2.78 μM
LTEA_HepaRG_CYP2C9LiverHuman1559CYP2C9Activatory0.55 μM
LTEA_HepaRG_CYP3A4LiverHuman1576CYP3A4Inhibitory3.92 μM
LTEA_HepaRG_CYP3A7LiverHuman1551CYP3A7Inhibitory1.43 μM
LTEA_HepaRG_UGT1A1LiverHuman54658UGT1A1Inhibitory2.03 μM

ToxCast endpoints for intended target type: Protein
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CCTE_Deisenroth_AIME_384WELL_LUC_ActiveMammary gland/breastHuman2099ESR1Gain5.0 μM
CCTE_Deisenroth_AIME_384WELL_LUC_InactiveMammary gland/breastHuman2099ESR1Gain7.68 μM
ATG_ERE_CISLiverHuman2099ESR1Inhibitory5.07 μM
ATG_PXRE_CISLiverHuman8856NR1I2Inhibitory4.13 μM
ATG_ERa_TRANSLiverHuman2099ESR1Gain5.32 μM
BSK_CASM3C_ThrombomodulinVascularHuman7056THBDInhibitory6.61 μM
BSK_hDFCGF_CollagenIIISkinHuman1281COL3A1Inhibitory10.4 μM
BSK_hDFCGF_PAI1SkinHuman5054SERPINE1Inhibitory8.38 μM
BSK_hDFCGF_VCAM1SkinHuman7412VCAM1Inhibitory9.94 μM
ATG_hERa_XSP1LiverHuman2099ESR1Gain1.12 μM
ATG_mPXR_XSP1LiverHuman8856NR1I2Gain2.67 μM
ATG_mPXR_XSP2LiverHuman8856NR1I2Gain4.54 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain8.39 μM
TOX21_ERb_BLA_Antagonist_ratioKidneyHuman2100ESR2Loss7.49 μM
TOX21_PR_BLA_Antagonist_ratioKidneyHuman5241PGRLoss8.95 μM
TOX21_p450_CYP2C19_AntagonistHuman1557CYP2C19Loss0.06 μM
TOX21_p450_CYP2C9_AntagonistHuman1559CYP2C9Loss4.76 μM
TOX21_hERG_U2OS_AntagonistBoneHuman3757KCNH2Loss9.77 μM
TOX21_ERa_LUC_VM7_AgonistBreastHuman2099ESR1Gain5.16 μM
TOX21_ERb_BLA_Antagonist_ratioKidneyHuman2100ESR2Loss7.06 μM
TOX21_PR_BLA_Antagonist_ratioKidneyHuman5241PGRLoss5.06 μM
TOX21_p450_CYP2C19_AntagonistHuman1557CYP2C19Loss0.04 μM
TOX21_p450_CYP2C9_AntagonistHuman1559CYP2C9Loss4.37 μM
TOX21_PR_BLA_Antagonist_ratioKidneyHuman5241PGRLoss6.83 μM
TOX21_p450_CYP2C19_AntagonistHuman1557CYP2C19Loss0.05 μM
TOX21_p450_CYP2C9_AntagonistHuman1559CYP2C9Loss5.65 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
OT_ERa_GFPERaERE_0120CervixHuman2099ESR1Gain3.72 μM
OT_ERa_GFPERaERE_0480CervixHuman2099ESR1Gain3.22 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratioOvaryChinese hamster3014H2AXGain146.96 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratioOvaryChinese hamster3014H2AXGain123.44 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.